Skip to main content
. Author manuscript; available in PMC: 2020 Apr 1.
Published in final edited form as: Neuropharmacology. 2019 Jan 3;148:139–150. doi: 10.1016/j.neuropharm.2018.12.031

Figure 6.

Figure 6.

Grouped and individual active nosepoke entries during the final reinstatement round (N=20). *Indicates significant difference from 0 mg/kg. Chamber locomotion on panels A and B is visualized using a point size with all point sizes normalized across these panels for accuracy and ease of visual data assessment between these panels.